Lansoprazole / naproxen Pregnancy and Breastfeeding Warnings

Brand names: Prevacid NapraPAC, Prevacid NapraPAC 375, Prevacid NapraPAC 500

Lansoprazole / naproxen Pregnancy Warnings

Lansoprazole-naproxen has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Naproxen use in late in pregnancy may cause premature closure of the ductus arteriosus and prolong labor and delivery. Lansoprazole-naproxen is only recommended during pregnancy when there is no alternative and benefits outweigh risks.

See references

Lansoprazole / naproxen Breastfeeding Warnings

There are no data on the excretion of lansoprazole into human milk. Naproxen is excreted into human milk in very small amounts. The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentrations in plasma. The manufacturer recommends that, due to the adverse reaction of prostaglandin-inhibiting drugs on neonates, the use lansoprazole-naproxen in nursing women should be avoided.

Naproxen anion concentrations of approximately 1% of that found in plasma have been found in the milk of lactating women.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer